FHD-286 in Subjects With Metastatic Uveal Melanoma
NCT04879017
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
76
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor terminated the study for business reasons.
Conditions
Metastatic Uveal Melanoma
Interventions
DRUG:
FHD-286
Sponsor
Foghorn Therapeutics Inc.